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SUMMARY
We followed up a cohort of 446 toxoplasma-infected pregnant women to determine the median
and variability of the duration of positive toxoplasma–IgM (immunoglobulin M) results
measured by an immunoﬂuorescence test (IFT) and an immunosorbent agglutination assay
(ISAGA). IgM antibodies were detected for longer using the ISAGA test [median 12.8 months,
interquartile range (IQR) 6.9–24.9] than the IFT (median 10.4, IQR 7.1–14.4), but the variability
between individuals in the duration of IgM positivity was greatest for the ISAGA test.
IgM-positive results persisted beyond 2 years in a substantial minority of women (27.1% ISAGA,
9.1% IFT). Variation in the duration of the IgM response measured by ISAGA and IFT limit
their usefulness for predicting the timing of infection in pregnant women. However, measurement
of IgM and IgG antibodies in a cross-sectional serosurvey oﬀers an eﬃcient method for
estimating the incidence of toxoplasma infection.
INTRODUCTION
Toxoplasma gondii is a ubiquitous protozoan parasite
acquired from undercooked meat, or from food or
water contaminated by toxoplasma oocysts [1, 2].
Infection can be transmitted to the foetus by women
who ﬁrst acquire toxoplasmosis during pregnancy,
although the risk of mother-to-child transmission de-
pends on the gestational age at maternal infection [3].
As maternal infection is usually asymptomatic, sero-
logical tests for toxoplasma-speciﬁc immunoglobulin
M (IgM) and IgG are used to identify women infected
during pregnancy. IgM antibodies can be detected
approximately 14 days after acquisition of toxo-
plasma infection [4] and decline to undetectable levels
several months later depending on the test used [1, 4].
In contrast, IgG antibodies are detectable 14 days
after the ﬁrst positive IgM test [3] and persist indeﬁ-
nitely. Consequently, IgM results are widely used,
together with other serological results such as IgG
titre and avidity [1, 4] to estimate the timing of
maternal infection.
Information on the timing of infection provided by
IgM results can also be used to estimate the incidence
of infection in cross-sectional studies based on a single
serosurvey [5]. Alternative methods for measuring
the incidence of maternal infection are problematic.
Follow-up studies to measure seroconversion (change
from negative to positive antibodies) are expensive
and time-consuming [6]. On the other hand, model-
ling using cross-sectional data on age-speciﬁc IgG
prevalence overestimates incidence due the sharp
decline in seroprevalence in pregnant women over
the last 3 decades [7, 8].
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Use of IgM results for these clinical and epidemi-
ological applications requires information on the
average duration of the IgM response and how much
this varies between individuals. For example, a test
result with a long mean duration but with little
variability might be more useful for timing maternal
infection than one with a short mean duration but
with large variability.
Several studies have reported a minimum duration
of speciﬁc IgM, but none have followed up subjects
for long enough to detect reversion to negativity in
more than a handful of individuals [9–11]. No pre-
vious reports of the variability of toxoplasma-speciﬁc
IgM duration could be found. We therefore studied
a large cohort of women who acquired toxoplasma
infection during pregnancy and whose IgM status was
followed up long-term. The aim was to determine
the median and variability of the duration of positive
toxoplasma–IgM results measured by two tests : an
automated immunoﬂuorescence test (IFT) [12] and an
immunosorbent agglutination assay (ISAGA–IgM;
bioMe´rieux, Marcy, France) [13]. We show how the
results can be used to help clinicians identify women
at high risk of post-conceptional toxoplasma infec-
tion and to estimate the incidence ofmaternal infection
in cross-sectional serosurveys.
MATERIALS AND METHODS
Study population
The study is based on a cohort of 788 toxoplasma-
infected pregnant women identiﬁed by routine pre-
natal testing for maternal toxoplasma infection in
Lyon, France between 1987 and 1995. Over 90% of
the women received antibiotic treatment for toxoplas-
mosis during pregnancy. Serum samples were taken
from the mother at monthly follow-up visits during
pregnancy and, for a subsample, when the child was
seen for clinical assessment (usually at the 2-month
paediatric assessment) in order to compare maternal
antibody responses with those of the child. Further
details of the cohort, and details of the ISAGA and
IFT are reported elsewhere [3, 12–14].
Measurement of IgM duration
For each test (ISAGA and IFT), four dates were
extracted: the last IgM-negative test and ﬁrst IgM-
positive test (these dates bound the interval in which
initial maternal seroconversion occurred), and the last
IgM-positive test and ﬁrst IgM-negative test (these
dates bound the interval in which the change to IgM
negativity occurred). Women not observed to sero-
convert (change from negative to positive IgM) were
deleted from the analysis unless : (a) their child was
infected, in which case the last negative test was as-
sumed to have occurred at conception; and (b) the
ﬁrst IgM test was positive but all IgG tests on the
same date were negative, in which case the last nega-
tive IgM test was assumed to be dated 3 weeks pre-
viously. Not all women were followed up long enough
to observe the change back from positive to negative
IgM antibody (right-censored cases) but provide
information on the minimum duration of IgM posi-
tivity and were included in the analysis (see Statistical
analysis section below). In cases where only one posi-
tive sample was observed, the date of the ﬁrst and last
IgM-positive test was the same. We used the manu-
facturer’s recommended cut-oﬀ for the ISAGA test
and previously reported cut-oﬀs for the IFT [12]. The
cut-oﬀ values used for the ISAGA were 0–5 IU/ml
(negative), 6–8 IU/ml (equivocal) and 9–12 IU/ml
(positive). For the IFT this was 0 IU/ml (negative),
0–6.4 IU/ml (equivocal) and more than 6.4 IU/ml
(positive). Equivocal values were excluded from the
analysis since treating them arbitrarily as positive or
negative test results would lead to spuriously precise
observations and might bias the point estimates of the
cumulative distribution function of duration of IgM
positivity as well as reducing their standard errors.
Statistical analysis
Standard survival analysis could not be used to de-
termine the duration of IgM-positive results as the
exact moment of change of IgM antibody from nega-
tive to positive or back from positive to negative was
not observed. Analyses were therefore performed
using non-parametric methods for doubly interval-
censored data [15].
We determined the duration of IgM positivity for
each test type, whether the woman gave birth to an
infected child or not, and whether she had received
prenatal treatment with a combination of pyrimeth-
amine–sulphonamide or spiramycin. These latter
analyses were based on the hypothesis that women
with an infected foetus experience a more pronounced
or prolonged immunological stimulation and, sec-
ondly, based on clinical observations that pyrimeth-
amine suppresses the immunological response.
In order to test for diﬀerences in the duration of
IgM positivity between tests, the child’s infection
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status and type of treatment, we used the multiple
imputation approach to Cox regression with doubly
censored data proposed by Pan [16]. We used 1000
imputed data-sets in all the analyses and performed
the goodness-of-ﬁt tests for the imputed Cox pro-
portional hazard models based on a x2(1) statistic. The
latter tests for departures of the proportionality of
hazard assumption required by the Cox models. The
Cox regression models and the goodness-of-ﬁt tests
were calculated using R in a Unix environment; the
programs were modiﬁed versions of those reported by
Pan [16].
To estimate incidence from one cross-sectional
sample we used the formula for estimating recent in-
cidence from Kaplan and Brookmeyer [5]. However,
for this method to be useful the average duration
of IgM positivity needs to be suﬃciently small (e.g.
maximum 2 years). As some women in this study
did not revert to negativity, the average duration of
positive IgM results presented in this study is inﬁnite.
We therefore modiﬁed the method of Kaplan and
Brookmeyer to adjust for positive IgM results for
longer than 2 years.
To estimate the incidence in the period t times unit
prior to the sampling date the following modiﬁcation
to Kaplan and Brookmeyer’s estimate can be used:
r(xtt)=
pp(1xmt)
(1xp)tt
, (1)
where r(xtt) denotes the incidence as a fraction of the
uninfected population between the sampling date and
the period t time units prior to the sampling date, p is
the fraction of IgG-positive persons in the population
(prevalence of the infection), p is the fraction of IgM-
positive persons among IgG-positive persons, tt is
the average duration of IgM positivity, given that the
duration was at most t time units, and mt is the frac-
tion of IgM-positive persons with an IgM-positive
duration longer than t time units, among all IgM-
positive persons. mt and tt can be computed from the
results in this paper whilst p and p can be estimated
from one cross-sectional sample. The modiﬁcation
adjusts for IgM positivity longer than t time units
by multiplying the fraction of IgM-positive persons
among IgG-positive persons in the serosurvey with
the estimated fraction of IgM-positive persons with
IgM positivity shorter than t time units. The average
duration of IgM positivity (tt) is then calculated,
conditional on the duration lasting at most t time
units. The method assumes that the infection rate is
approximately constant over the sampling period.
Let n, n+, and nM be the numbers of individuals
tested, IgG positive and IgM positive among those
IgG positive respectively. Then the estimated preva-
lence is pˆ=n+/n, and pˆ=nM/n+ is the estimated
fraction of IgM positives among the IgG-positive in-
dividuals. mˆt is the estimated fraction of IgM-positive
persons with an IgM positivity longer than t time
units among all IgM positives and tˆt is the estimated
average duration of IgM positivity conditional on it
being less than or equal to t time units (both are esti-
mated in this paper). Applying the delta method [17]
to the logarithm of eqn (1), assuming that mˆt and pˆ
are independent, yields an estimate for the asymptotic
variance of the estimate of the log-incidence as:
nˆ=bvar( ln ( rˆ(x tˆt)))= 1
(1x pˆ) pˆn
+
1
nM
mˆt
1x mˆ
+
1x pˆ
pˆ
 
+bvar(tt)
tˆ2t
,
and an asymptotic 95% conﬁdence interval (CI) is
given by [ rˆ(x tˆt)ex196
ﬃﬃˆ
v
p
, rˆ(x tˆt)e196
ﬃﬃˆ
n
p
].
RESULTS
Of the 788 toxoplasma-infected women in the cohort,
342 were excluded as they were not observed to
change from negative to positive IgM (no initial
negative test was available) and did not give birth to
an infected child. Of the remaining 446 women who
seroconverted during or shortly before pregnancy,
182 (41%) gave birth to a child with congenital
toxoplasmosis [241 were uninfected and 23/446 (5%)
children had insuﬃcient follow up to determine con-
genital infection status]. Prenatal treatment was pre-
scribed to 415/446 (93%) women, of whom 98/415
(24%) were prescribed pyrimethamine–sulphadiazine.
The median duration of follow-up from the ﬁrst
negative IgM test or conception to the last IgM test
was 11 months (range 1–81 months).
Table 1 shows the number of women analysed
according to test type. As testing depended on lab-
oratory practice, women were not always tested with
both tests. A total of 102 women (25%) reverted to
a negative test result with the ISAGA test and 105
(29%) did so with the IFT. Figure 1 shows the
cumulative distribution function of the duration of
IgM positivity according to the two tests. The diﬀer-
ence in duration between both tests was signiﬁcant
(P<0.0001). The y-axis shows the percentage of
women with IgM positivity lasting less than the
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time-period plotted on the x-axis. IgM antibodies
were detected for longer by the ISAGA test compared
to the IFT. For example, 50% of women had positive
ISAGA results for less than 12.8 months [interquartile
range (IQR) 6.9–24.9 months] and positive IFT
results for less than 10.4 months (IQR 7.1–14.4
months). The steeper the gradient of the slope of the
cumulative distribution function, the less variability
between individuals in the duration of IgM. Com-
parison of the gradient for the IFT and ISAGA test
shows that the variability between individuals was
smaller for the IFT than the ISAGA test. An esti-
mated 27.1% of women (95% CI 19.2–38.3) had a
positive ISAGA result, and 9.1% (95% CI 4.9–16.5)
had a positive IFT result lasting longer than 2 years.
Conﬁdence intervals around these estimates are wide
due to the small number of women with a suﬃciently
long follow-up.
Figure 2(a, b) shows that IgM antibodies were de-
tected for longer using both tests in women who gave
birth to an infected, compared to an uninfected, child.
However, diﬀerences in the duration of positivity
according to congenital infection status were not
signiﬁcant for either test (P=0.34 and P=0.32 for
IFT and ISAGA respectively). Using the ISAGA
test (Fig. 2b), IgM was detected for less than 11.7
months (IQR 6.7–18.5 months) in 50% of women
with an uninfected child compared to 13.1 months
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Fig. 1. Duration of detection of IgM antibodies and 95%
CIs using the IFT (––), and the ISAGA test (– – –).
Table 1. Number of women analysed according to
IgM test type (446 women were studied)
Pattern of results* ISAGA IFT
x+x orx++x 102 (25%) 105 (29%)
x+ orx++ (censored) 312 (75%) 254 (71%)
Total 414 359
ISAGA, Immunosorbent agglutination assay ; IFT, Immu-
noﬂuorescence test.
* x, Negative ;+, positive.
x+xorx++x, Women in whom the initial change from
negative to positive IgM was observed, as well as the change
back from positivity to negativity.
x+ or x++, Women in whom the initial change from
negative to positive IgM was observed, but were not fol-
lowed up long enough to observe any change back from
positivity to negativity.
x+x andx+, Only one positive test observed.
x++x andx++, More than one positive test observed.
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Fig. 2. Comparison of the duration of detection of IgM
antibodies in women who gave birth to infected (– – –) vs.
uninfected children (––). (a) Compares women tested with
the IFT; (b) compares women tested with the ISAGA test.
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(IQR 7.5–31.3 months) for 50% of those with an
infected child. Corresponding values for the IFT
(Fig. 2a) were 7.3 months for 50% of women with
an infected child (IQR 5.7–13.3) compared to 8.6
months for 50% of those with an uninfected child
(IQR 5.2–12.5 months).
The distribution function for IgM duration in
women treated with pyrimethamine–sulphonamide
compared to spiramycin was similar for both test
types [Fig. 3(a, b) ; P=0.76, and P=0.29 for IFT and
ISAGA respectively].
Table 2 shows the values for the regression coef-
ﬁcients for the three comparisons between tests,
congenital infection status of the child, and type of
prenatal treatment, as well as the goodness-of-ﬁt
statistic. The P value of the goodness-of-ﬁt statistic
for all comparisons performed was bigger than 0.05
indicating that there was no evidence against the
proportional hazards assumption.
DISCUSSION
IgM antibodies were detected for a signiﬁcantly
longer time using the ISAGA test than the IFT, but
the variability between individuals in the duration
of IgM positivity was greatest for the ISAGA test.
There was a substantial minority of women with
long-term persistence of IgM of unknown duration.
There was no signiﬁcant diﬀerence in the duration of
IgM between women who gave birth to an infected,
compared to an uninfected child, nor between
women treated with pyrimethamine–sulphonamide or
spiramycin, although small sample size limited the
power to detect a diﬀerence.
The implications of our ﬁndings for a woman with
a positive IgM and IgG test at her ﬁrst prenatal visit
are that the risk of post-conceptional infection is
small but uncertain. Using the estimates in Figure 1,
the risk of post-conceptional infection for a woman
who is ﬁrst tested at 3 months’ gestation, is less than
1.3% (95% CI 0.6–2.1) given a positive ISAGA IgM
result, and less than 3.1% (95% CI 0.7–4.6) given a
positive IFT result. A positive IgM test result based
on a single sample in the ﬁrst trimester therefore
provides insuﬃcient information to identify women
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Fig. 3. Comparison of the duration of detection of IgM
antibodies in women treated with pyrimethamine–sulphon
amide at any point during pregnancy (––) vs. those treated
with spiramycin alone (– – –). (a) Compares women tested
with the IFT; (b) compares women tested with the ISAGA
test.
Table 2. Estimates of the regression coeﬃcient and
the goodness-of-ﬁt tests
Comparison
Regression coeﬃcient
Goodness-of-
ﬁt test
bˆ S.E. bˆ P value x2(1) P value
IFT vs.
ISAGA
x0.626 0.140<0.0001 0.390 0.53
Congenital infection status
IFT x0.192 0.202 0.34 0.005 0.94
ISAGA x0.206 0.212 0.32 0.001 0.99
Treatment (spiramycin alone vs. pyrimethamine–sulphon-
amide)
IFT x0.069 0.2362 0.76 1.261 0.26
ISAGA x0.278 0.2625 0.29 0.027 0.86
ISAGA, Immunosorbent agglutination assay ; IFT, Immu-
noﬂuorescence test.
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in whom further investigation, termination of preg-
nancy or treatment for toxoplasma infection may be
justiﬁed.
A strength of our study was that measurement of
IgM was routinely performed and was not conditional
on clinical characteristics in the mother or child. In
addition, the interval during which seroconversion
occurred was clearly deﬁned. A weakness is that,
as 93% of women were prescribed treatment during
pregnancy, we were unable to determine IgM dur-
ation in untreated women. Previous statements that
treatment suppresses the IgM response [4, 18] appear
to be based on clinical experience and no evidence has
been published of diﬀerential eﬀects according to the
type of treatment.
This is the ﬁrst published report of which we are
aware of the distribution of the duration of IgM
positivity measured by ISAGA or IFT in a population
followed for long enough to detect reversion to nega-
tivity in more than ﬁve individuals. Nevertheless,
comparison of previous follow-up studies of indi-
viduals with well-documented dates of infection can
be instructive. Jenum et al. [9] found that 25% (5/27)
of women reverted to ISAGA negative results be-
tween 14 and 31 weeks after infection, in agreement
with our estimate (see Fig. 1) of 25% with IgM lasting
less than 7 months (30 weeks). In contrast, Sulzer
et al. [10] reported that 3/16 (19%) individuals
reverted to IgM negativity by the IFT within 10.5
months of a waterborne outbreak of toxoplasmosis,
whereas we estimated that 50% of women were
negative 10.4 months after infection (Fig. 1). The
discrepancy may reﬂect error due to the small number
studied by Sulzer et al. Alternative explanations
include prolonged persistence of IgM due to infection
acquired by ingesting oocysts compared to tissue cysts
from undercooked meat, which is most commonly
associated with infections in pregnancy [2]. Further
possibilities are improved sensitivity of the test or
gender diﬀerences in immune response [19–21], as
Sulzer et al.’s report was conﬁned to men.
Our ﬁndings can be used to estimate the incidence
of toxoplasma infection in cross-sectional studies
based on a single serum sample from individuals
tested for speciﬁc IgG and IgM antibodies, using
statistical methods reported elsewhere [5, 22, 23].
Because of the risk of false-positive IgM results [1]
positive tests should be conﬁrmed by a second test
and only included if the individual is also IgG posi-
tive. In view of the marked geographical and secular
trends in seroprevalence, this method oﬀers a
low-cost, standardized approach with which to com-
pare the burden of disease in diﬀerent populations
and to evaluate preventive measures. However, extra-
polation of the method beyond pregnant women in
a western industrialized country to other populations
should be made with caution in view of the hypothesis
that diﬀerences in the immune response or type of
organism exposure may aﬀect the duration of IgM
seropositivity. Investigation of the latter would be
assisted by tests able to distinguish between infection
acquired from oocysts or tissue cysts.
The sample size needed for such a study depends
on the prevalence of toxoplasmosis, the fraction of
IgM-positive results among IgG-positive individuals,
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Fig. 4. The 95% CIs are given for the estimated yearly in-
cidence (y-axis) from one cross-sectional sample using the
IgM IFT and assuming a fraction of IgM positives among
IgG positives of 0.8% (a) and 3.4% (b). Further assump-
tions are : a prevalence of IgG positives of 10% in the
population, average duration of IgM positivity, given that
the duration is shorter than 2 years equals 8.3/12 years
(variance 5.8/144) and the proportion of women whose
IgM-positive results lasts longer than 2 years is 9.1%.
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and the incidence and average duration of IgM posi-
tivity. For these calculations, average duration of
ISAGA positivity, given that the duration was shorter
than 2 years, was 10.2 months (95% CI 10.0–10.4)
and for IFT 8.3 months (95% CI 7.2–8.9). The esti-
mated proportion of women with a duration longer
than 2 years was 27.1% (95% CI 19.2–38.3) with the
ISAGA test, and 9.1% (95% CI 4.9–16.5) with
the IFT. Figure 4(a, b) shows the 95% CIs around
the estimated incidence using the above-mentioned
ﬁgures for the IFT according to sample size. To illus-
trate the method, we assumed that the prevalence of
IgG was 10%. We used two sources that give diﬀerent
results for the proportion of IgG-positive individuals
who were IgM positive (3.49% [24], Fig. 4b and
0.81% [25], Fig. 4a). The ﬁgures show that for a
sample size of 10 000, given the assumptions above,
the estimated incidence would be 1.1/1000 susceptible
women/year (95% CI 0.5/1000 to 2.8/1000) and for
Fig. 4b, 5.1/1000 susceptible women/year (95% CI
2.6/1000 to 9.8/1000). The sample size needed could
be further reduced if additional research provided
more precise estimates for the mean duration of IgM
positivity.
CONCLUSION
Variability in the duration of the IgM response
measured by ISAGA and IFT limit their usefulness
for predicting the timing of infection in pregnant
women. The decision to terminate the pregnancy or
oﬀer therapy to reduce the risk of transmission should
not be based on a single IgM- and IgG-positive test
result alone. However, measurement of IgM and IgG
antibodies in a cross-sectional serosurvey oﬀers an
eﬃcient method for estimating the incidence of toxo-
plasma infection in populations.
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